These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28712668)

  • 1. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.
    Alene KA; Viney K; McBryde ES; Tsegaye AT; Clements AC
    Trop Med Int Health; 2017 Mar; 22(3):351-362. PubMed ID: 27978594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
    Kliiman K; Altraja A
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
    BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan.
    Khan MA; Mehreen S; Basit A; Khan RA; Jan F; Ullah I; Ihtesham M; Khan A; Ullah U; Javaid A
    Saudi Med J; 2015 Dec; 36(12):1463-71. PubMed ID: 26620989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of anti-tuberculosis drug resistance on treatment outcome of pulmonary tuberculosis patients receiving directly observed treatment strategy in Henan Province, China].
    Wang GJ; Xu JY; Wang GB; Zhen XA; Gao SY; Du CM
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):527-30. PubMed ID: 17074265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China: A retrospective cohort study.
    Li Q; Lu M; Hsieh E; Wu L; Wu Y; Wang M; Wang L; Zhao G; Xie L; Qian HZ
    Medicine (Baltimore); 2020 Dec; 99(50):e23649. PubMed ID: 33327347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes.
    Perez-Navarro LM; Restrepo BI; Fuentes-Dominguez FJ; Duggirala R; Morales-Romero J; López-Alvarenga JC; Comas I; Zenteno-Cuevas R
    Tuberculosis (Edinb); 2017 Mar; 103():83-91. PubMed ID: 28237037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
    Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
    Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China.
    Sun Y; Harley D; Vally H; Sleigh A
    PLoS One; 2017; 12(1):e0168865. PubMed ID: 28118372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
    Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
    J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proportions and Risk Factors of Developing Multidrug Resistance Among Patients with Tuberculosis in China: A Population-Based Case-Control Study.
    Huai P; Huang X; Cheng J; Zhang C; Wang K; Wang X; Yang L; Deng Z; Ma W
    Microb Drug Resist; 2016 Dec; 22(8):717-726. PubMed ID: 27058017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
    Kibret KT; Moges Y; Memiah P; Biadgilign S
    Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.